Shukra Pharmaceuticals Share Price | Shukra Pharmaceuticals Stock Screener
SHUKRAPHAR
Pharmaceuticals
Share Price BSE
₹31.72
▼
-0.60 (-1.86%)
As of July 24, 2026, the Shukra Pharmaceuticals share price (BSE: SHUKRAPHAR) is ₹31.72, down 1.86% from the previous close, with shares trading between ₹31.11 and ₹32.59, and a 52-week range of ₹17.95–₹64.43.
Analyse SHUKRAPHAR stock price history and track historical price performance.
Use the Shukra Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Shukra Pharmaceuticals Market Cap
₹1,445.88 Cr.
SHUKRAPHAR P/E Ratio (TTM)
66.26
Shukra Pharmaceuticals P/B Ratio
16.15
EPS (TTM)
₹0.50
Dividend Yield
0.03%
Debt to Equity
0.06
SHUKRAPHAR 52 Week High
₹64.43
Shukra Pharmaceuticals 52 Week Low
₹17.95
Operating Margin
11.00%
Profit Margin
-28.57%
SHUKRAPHAR Revenue (TTM)
₹7.00
EBITDA
₹2.00
Net Income
₹-2.00
Total Assets
₹117.00
Total Equity
₹90.00
Shukra Pharmaceuticals Share Price Chart
Screen Shukra Pharmaceuticals share price with an interactive chart. Analyse SHUKRAPHAR price trends and volatility across different timeframes.
Shukra Pharmaceuticals Company Profile - Fundamental Screener
Screen Shukra Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SHUKRAPHAR shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE551C01044
Shukra Pharmaceuticals Balance Sheet Screener
Screen SHUKRAPHAR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 117 | 87 | 78 | 75 | 35 | 36 | 34 | 28 | 24 | 19 |
| Current Assets | 84 | 65 | 56 | 53 | 16 | 16 | 15 | 11 | 8 | 7 |
| Fixed Assets | 34 | 19 | 20 | 20 | 18 | 18 | 17 | 16 | 14 | 10 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 5 | 7 | 6 | 7 | 6 | 13 | 11 | 9 | 6 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 90 | 63 | 58 | 25 | 16 | 16 | 15 | 15 | 15 | 15 |
| Share Capital | 44 | 44 | 11 | 4 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves & Surplus | 46 | 19 | 47 | 21 | 15 | 14 | 14 | 14 | 13 | 13 |
Shukra Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Shukra Pharmaceuticals income statement and profit fundamentals.
Analyze SHUKRAPHAR quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Shukra Pharmaceuticals share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|
| Revenue | 7 | 40 | 8 | 7 | 15 | 12 |
| Expenses | 6 | 12 | 6 | 4 | 6 | 7 |
| EBITDA | 2 | 28 | 1 | 2 | 9 | 5 |
| Operating Profit % | 11.00% | 69.00% | -7.00% | 24.00% | 55.00% | 37.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 27 | 0 | 1 | 8 | 4 |
| Tax | 2 | 7 | -2 | 0 | 2 | 1 |
| Net Profit | -2 | 20 | 2 | 1 | 5 | 3 |
| EPS | -0.04 | 0.47 | 0.05 | 0.02 | 0.12 | 0.72 |
Shukra Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SHUKRAPHAR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 8 | -5 | 3 | 8 | 1 | 1 | 0 | 1 | 0 | 3 |
| Investing Activities | -1 | -1 | -4 | -2 | -2 | -3 | -3 | -5 | -1 | 0 |
| Financing Activities | -5 | 12 | 5 | -7 | 2 | 2 | 2 | 4 | 0 | -1 |
| Net Cash Flow | 2 | 6 | 4 | 0 | 0 | 0 | 0 | -1 | -1 | 1 |
Shukra Pharmaceuticals Shareholding Pattern Screener
See Shukra Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Shukra Pharmaceuticals promoter holding and ownership changes for SHUKRAPHAR on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 9.37% | 9.43% | 9.20% | 28.69% | 9.29% | 9.41% | 9.25% | 9.19% |
| Other Holding | 39.56% | 39.50% | 39.72% | 20.24% | 39.64% | 39.51% | 39.68% | 39.73% |
| Shareholder Count | 27,173 | 25,649 | 21,441 | 20,337 | 18,231 | 17,844 | 16,321 | 14,989 |
Shukra Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Shukra Pharmaceuticals dividend history with payout and yield data.
View Shukra Pharmaceuticals dividend details including ex-dates and amounts for SHUKRAPHAR stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.01 | 0.03% |
| 2024-March | ₹1.00 | 4.58% |
| 2023-March | ₹0.50 | 6.13% |
| 2022-March | ₹0.50 | 42.74% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.50 | 208.33% |
| 2018-March | ₹0.50 | 263.16% |
| 2017-March | ₹0.50 | 156.25% |
Shukra Pharmaceuticals Stock Index Membership
See which indices include Shukra Pharmaceuticals stock.
Check SHUKRAPHAR index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Shukra Pharmaceuticals Market Events Screener - Corporate Actions
Get Shukra Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Shukra Pharmaceuticals stock events that may affect SHUKRAPHAR share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-06 | 2026-07-06 | Extraordinary General Meeting | NA | 2.92% |
| 2026-05-07 | 2026-05-07 | Quarterly Result Announcement | NA | 13.62% |
| 2026-02-04 | 2026-02-04 | Quarterly Result Announcement | NA | -7.11% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.17% |
| 2025-11-01 | 2025-11-01 | Extraordinary General Meeting | NA | 19.04% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | 34.10% |
| 2025-09-18 | 2025-09-18 | Dividend | ₹ 0.01 /share | 126.55% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -9.76% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | -5.08% |
| 2025-03-21 | 2025-01-29 | Split | 1:10 | 0.00% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -9.64% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -6.35% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 5.63% |
| 2024-09-23 | 2024-09-24 | Dividend | ₹ 1.00 /share | -40.51% |
| 2024-08-23 | 2024-08-23 | Extraordinary General Meeting | NA | -31.85% |
Shukra Pharmaceuticals Competitors Screener - Peer Comparison
Screen SHUKRAPHAR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 469,622 | 40.30 | 61,674 | 12.69% | 11,565 | 62.67 |
| Divis Laboratories | 194,655 | 75.03 | 10,560 | 8.73% | 2,520 | 69.61 |
| Torrent Pharmaceuticals | 190,519 | 75.44 | 13,886 | 20.34% | 2,138 | 53.08 |
| Cipla | 116,483 | 29.67 | 29,045 | 2.24% | 3,870 | 48.42 |
| Zydus Life Science | 115,687 | 22.25 | 27,658 | 17.64% | 5,026 | 59.19 |
| Lupin | 113,247 | 20.85 | 29,039 | 26.75% | 5,356 | 54.70 |
| Mankind Pharma | 105,954 | 53.09 | 14,636 | 14.85% | 1,938 | 50.34 |
| Dr Reddys Laboratories | 102,113 | 24.31 | 35,059 | 3.90% | 4,158 | 31.90 |
| Aurobindo Pharma | 89,816 | 25.44 | 33,385 | 3.21% | 3,376 | 50.49 |
| Laurus Labs | 84,115 | 92.82 | 6,868 | 22.01% | 890 | 59.60 |
Shukra Pharmaceuticals Company Announcements - News Screener
Screen SHUKRAPHAR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-20 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company Held On Monday July 14 2026 For Confirmation Of Receipt Of The Differential Upfront Consideration From The Allottees Pursuant To Regulation 170(2) Of The SEBI (ICDR) | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-06 | EGM Voting Results | - |
| 2026-07-06 | Shareholder Meeting / Postal Ballot-Outcome of EGM | - |
| 2026-06-23 | Closure of Trading Window | - |
| 2026-06-15 | Board Meeting Outcome for Appointment And Resignation Of Company Secretary & Compliance Officer | - |
| 2026-06-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-12 | Notice Of EGM To Be Held On 6Th July 2026 | - |
| 2026-06-10 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Wednesday June 10 2026 | - |
| 2026-06-05 | Board Meeting Intimation for Ratification Of Approval For Members Resolution Passed In The Extra-Ordinary General Meeting Dated 01St November 2025 | - |
| 2026-05-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-05-07 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-07 | Corporate Action-Board approves Dividend | - |
| 2026-05-07 | Regulation 32 For Starement Of Deviation | - |
| 2026-05-07 | Results For The Financial Year Ended March 31 2026 | - |
| 2026-05-07 | Board Meeting Outcome for Outcome For The Board Meeting Dated 07.05.2026 For The Audited Financial Results For The Quarter And Year Ended March 2026 | - |
| 2026-04-29 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-29 | Board Meeting Intimation for Audited Financial Result For The Quarter And Financial Year Ended On 31St March 2026 Along With The Auditors Report | - |
| 2026-04-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |